Across TCGA pan-cancer cohorts, RABGAP1L-DT RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RABGAP1L-DT’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RABGAP1L-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RABGAP1L-DT is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.
HNSC, KIRP, and KIRC are the cancer types where RABGAP1L-DT tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RABGAP1L-DT RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.